BIV1-CovIran 灭活病毒颗粒疫苗对 SARS-CoV-2 的疗效与安全性:随机、安慰剂对照、双盲、多中心 3 期临床试验
在伊朗六城市开展的随机、安慰剂对照、双盲、多中心 3 期试验中,20 000 名 18-75 岁参与者按 2:1 随机接种两剂 5 µg BIV1-CovIran 疫苗或安慰剂,间隔 28 天。总体对有症状 covid-19 的疗效为 50.2%(95%CI 44.7% 至 55.0%),对重症为 70.5%(63.7% 至 76.1%),对危重症为 83.1%(61.2% 至 93.5%)。接种耐受良好,未出现与注射相关的严重不良事件。
要点
- 两剂 5 µg BIV1-CovIran 疫苗对有症状 covid-19 的疗效为 50.2%(95%CI 44.7% 至 55.0%)。
- 对重症 covid-19 的疗效为 70.5%(95%CI 63.7% 至 76.1%),对危重症为 83.1%(95%CI 61.2% 至 93.5%)。
- 接种组严重不良事件与注射无关,多数不良反应为轻中度且自限。
核心结论
- 两剂 BIV1-CovIran 疫苗对有症状 covid-19 的疗效为 50.2%,对重症为 70.5%,对危重症为 83.1%。
- 接种耐受良好,未提出安全性担忧。
研究设计与样本
- 随机、安慰剂对照、双盲、多中心 3 期临床试验,在伊朗六城市开展。
- 20 000 名 18-75 岁参与者按 2:1 随机分配至干预组或安慰剂组。
- 干预为 5 µg 疫苗或安慰剂,间隔 28 天。
- 首例参与者首次注射于 2021 年 5 月 16 日在德黑兰,末例参与者末次注射于 2021 年 7 月 15 日在伊斯法罕。
主要发现
- 接种组 13 335 人(66.7%),安慰剂组 6665 人(33.3%);平均年龄 38.3 岁(标准差 11.2),女性 6913 人(34.6%)。
- 随访中位 83 天,接种组有症状 758 人(5.9%)、重症 144 人(1.1%)、危重症 7 人(0.1%)。
- 安慰剂组有症状 688 人(10.7%)、重症 221 人(3.4%)、危重症 19 人(0.3%)。
- 疗效人群安慰剂组报告 2 例死亡,干预组无死亡。
- 随访期间报告 41 922 起不良事件,其中 28 782 起(68.7%)为不良反应,19 363 起(67.3%)在干预组。
关键数值与推荐
- 对有症状 covid-19 的总体疗效为 50.2%(95%CI 44.7% 至 55.0%)。
- 对重症疾病的疗效为 70.5%(95%CI 63.7% 至 76.1%)。
- 对危重症的疗效为 83.1%(95%CI 61.2% 至 93.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine. DESIGN: Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. SETTING: In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan. PARTICIPANTS: 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1. INTERVENTION: 5 µg vaccine or placebo with the interval of 28 days. MAIN OUTCOME MEASURES: Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial. RESULTS: 20 000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13 335 (66.7%)) or placebo (n=6665 (33.3%)). Participants' mean age was 38.3 (standard deviation 11.2) years, and 6913 (34.6%) were female. Among vaccinated participants that had covid-19 reported during the follow-up (median 83 days), 758 (5.9%) had symptoms, 144 (1.1%) had severe infection, and seven (0.1%) were critical. Among participants who received placebo during the follow-up, 688 (10.7%) had symptoms, 221 (3.4%) had severe infection, and 19 (0.3%) were critical. Overall efficacy was 50.2% (95% confidence interval 44.7% to 55.0%) against symptomatic covid-19, 70.5% (63.7% to 76.1%) against severe disease, and 83.1% (61.2% to 93.5%) against critical cases. Two deaths were reported in the efficacy population in the placebo group, no deaths were from the intervention group. During follow-up, 41 922 adverse events were reported: 28 782 (68.7%) were adverse reactions, of which 19 363 (67.3%) were in the intervention group. Most adverse reactions were mild or moderate in severity (grade 1 or 2) and self-limiting. No serious adverse events were related to the injections. For variant investigation, of 119 participants positive for the SARS-CoV-2 variant, 106 (89.1%) were positive for the delta variant. CONCLUSIONS: A two dose regimen of the BIV1-CovIran vaccine conferred efficacy of 50.2% against symptomatic covid-19, 70.5% against severe disease, and 83.1% against critical disease. Vaccination was well tolerated, with no safety concerns raised. TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20201202049567N3. FUNDING: Shifa-Pharmed Industrial Group.
引用
- Mohraz M, Vahdat K, Ghamari SH, et al. Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial. BMJ. 2023. PMID: 37734752. doi:10.1136/bmj-2023-070464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。